Scleroderma Foundation

In This Issue

President Obama Announces New Initiatives on Disability

FDA Approves Metozolv

Clinical Trials

Use of Influenza A (H1N1) 2009 Monovalent Vaccine

Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis

Psychological Distress in Patients With Morphea and Eosinophilic Fasciitis

Scleroderma Student Essay Contest

Upcoming Events

Stepping Out Walks

Advocacy Update

PHOTO OF THE WEEK

Walkers from the 2009 Albany, N.Y. walk
Walkers from the 2009 Albany, N.Y. walk

Scleroderma Student Essay Contest

Choosing scleroderma as a research topic helps to not only spread the word about the disease, but also helps to inform others about how they too can join the fight against scleroderma. You can win a Wii system or even a trip to Boston!

Stepping Out to Cure Scleroderma Walks – There Are More Left!

Find a walk near you!

Scleroderma Legislation

Learn more about these bills.

S. 1545

H.R. 2408

Pfizer, Inc. Logo

2009 Communications Sponsor

Scleroderma Foundation eLetter

Friday, October 9, 2009– Issue #317

eLetter Archive

President Obama Announces New Initiatives During National Disability Employment Awareness Month

Disabled LogoTHE WHITE HOUSE
Office of the Press Secretary

FOR IMMEDIATE RELEASE
October 5, 2009

Washington, D.C. – President Obama announced that his Administration is taking several steps to ensure that there is fair and equal access to employment for all Americans, particularly the 54 million people in this country living with disabilities. The announcement comes during National Disability Employment Awareness Month.

FDA LogoFDA Approves Metozolv

RALEIGH, N.C.–(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for Metozolv ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. Metozolv ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4–12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy.

Clinical Trials

ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals.

Use of Influenza A (H1N1) 2009 Monovalent Vaccine

CDC LogoRecommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. Prepared by National Center for Immunization and Respiratory Diseases, CDC

This report provides recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of vaccine against infection with novel influenza A (H1N1) virus. Information on vaccination for seasonal influenza has been published previously (CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP], 2009. MMWR 2009;58[No. RR-8]). Vaccines against novel influenza A (H1N1) virus infection have not yet been licensed; however, licensed vaccine is expected to be available by mid-October 2009. On July 29, 2009, ACIP reviewed epidemiologic and clinical data to determine which population groups should be targeted initially for vaccination.

Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis

Journal of Rheumatology LogoObjective Raynaud’s phenomenon (RP) is an important clinical feature of systemic sclerosis (SSc) for which consistently effective therapies are lacking. The study was designed to assess the safety, tolerability, and efficacy of tadalafil, a selective, long acting type V cyclic GMP phosphodiesterase (PDE-5) inhibitor, in this clinical syndrome.

Archives of Dermatology Logo

Psychological Distress in Patients With Morphea and Eosinophilic Fasciitis

Objective  To examine the level of psychological distress and factors contributing to distress in patients with morphea or eosinophilic fasciitis.

Columbus Holiday Schedule for National Office

In observance of Columbus Day, the National Office will be closed Monday, October 12. We will reopen on Tuesday, October 13. Have a wonderful Holiday!

Upcoming Events

Oct. 10, (Sat.) Oregon Chapter Board Meeting (Portland, Ore.)
Oct. 11, (Sun.) "Stepping Out to Cure Scleroderma" Walk (Philadelphia, Pa.)
Oct. 11, (Sun.) Patient Education Day (Grand Rapids, Mich.)
Oct. 17, (Sat.) Joint Educational Conference with Tri-State Chapter (New Brunswick, N.J.)
Oct. 18, (Sun.) Jessica Reif Walk/Run" (St. Louis, Mo.)
Oct. 19, (Mon.) Cooking Up a Cure" Celebrity Chef Auction and Food Tasting! (Ravenswood, Ill.)
Oct. 23–24, (Fri. & Sat.) A Spooktacular Evening of Fun (Livonia, Mich.)
Oct. 30–Nov. 1 (Fri.–Sun.) Scleroderma Booth at Northwest Womens' Show (Portland, Ore.)
Complete SF Calendar

Scleroderma Foundation, 300 Rosewood Drive, Suite 105, Danvers, MA 01923
Phone 978-463-5843 · 800-722-HOPE (4673)

© Copyright 2001–2009 Scleroderma Foundation. All Rights Reserved.
Disclaimer. Privacy Policy. Webmaster


Donate Contact Us. eLetter Magazine Medical Archive
Online Support Community National Conference SF Store Home